Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QEAUM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RG7787
|
|||||
| Synonyms |
RG 7787; RG-7787
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Epidermoid cancer [ICD11:XH4CR9]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Pleural mesothelioma [ICD11:2C26]
Investigative
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Antibody Name |
Anti-MSLN Anti-ody Fab fragment
|
Antibody Info | ||||
| Antigen Name |
Mesothelin (MSLN)
|
Antigen Info | ||||
| Payload Name |
Pseudomonas exotoxin PE24
|
Payload Info | ||||
| Therapeutic Target |
Eukaryotic elongation factor 2 (EEF2)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A-431 cells | CVCL_0037 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.40 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC70 cells | CVCL_1270 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.70 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | AsPC-1 cells | CVCL_0152 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Breast carcinoma | SUM149PT cells | CVCL_3422 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.50 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A-431 cells | CVCL_0037 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.50 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Peritoneal malignant mesothelioma | HAY cells | CVCL_N813 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A-431 cells | CVCL_0037 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | . | L55S cells | Homo sapiens | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.70 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC70 cells | CVCL_1270 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Peritoneal malignant mesothelioma | HAY cells | CVCL_N813 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 6.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | . | L55S cells | Homo sapiens | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A-431 cells | CVCL_0037 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Peritoneal malignant mesothelioma | HAY cells | CVCL_N813 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | KLM-1 cells | CVCL_5146 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Breast carcinoma | SUM149PT cells | CVCL_3422 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 35.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Peritoneal malignant mesothelioma | HAY cells | CVCL_N813 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 40.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 40.00 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | AsPC-1 cells | CVCL_0152 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 100 ng/mL | Positive MSLN expression (MSLN+++/++) | ||
| Method Description |
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
|
||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | KB cells | CVCL_0372 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.